Posted by Michael Wonder on 01 Aug 2022
ALX Oncology’s evorpacept receives fast track designation from FDA as first-line treatment for head and neck squamous cell carcinoma
1 August 2022 - ALX Oncology today announced that the U.S. FDA has granted fast track designation to evorpacept, a next generation CD47 blocker, in combination with pembrolizumab for the first-line treatment of adult patients with PD-L1 positive advanced head and neck squamous cell carcinoma.
